A Novel Multi-Component Formulation Reduces Inflammation In Vitro and Clinically Lessens the Symptoms of Chronic...

Area of Science:

• Dermatology
• Immunology
• Biochemistry

Background:

• Long-term treatments for inflammatory skin conditions like atopic dermatitis and eczema can lead to adverse effects.
• There is a need for safer and effective therapeutic options for managing chronic eczematous skin.

Purpose of the Study:

• To investigate the anti-inflammatory potential of Super Protein Multifunction (SPM) for managing skin inflammation.
• To evaluate the efficacy of SPM in a preclinical skin model and a randomized controlled clinical trial.

Main Methods:

• In vitro assessment of SPM's effect on pro-inflammatory cytokine expression (IL-1β, IL-6, IL-33, IL-1α, TSLP, TNFα) in HaCaT keratinocytes and Hs27 fibroblasts using RT-PCR.
• ELISA measurement of cytokine release in a UVB-irradiated 3D human skin model.
• A 3-week, double-blind, vehicle-controlled trial involving 20 patients with mild eczematous skin, assessing clinical outcomes (IGA, PA, DLQI, VAS) and histological changes.

Main Results:

• SPM significantly inhibited the expression and release of multiple pro-inflammatory cytokines in vitro.
• The clinical trial demonstrated significant improvements in Investigator's Global Assessment (IGA), Physician's Assessment (PA), and Dermatology Life Quality Index (DLQI) scores in the SPM group compared to vehicle.
• Histological analysis revealed reduced stratum corneum thickness and inflammatory cell infiltration in the SPM-treated group. No significant difference in pruritus (VAS) was observed between groups.

Conclusions:

• SPM exhibits potent anti-inflammatory properties, effectively reducing key inflammatory mediators.
• SPM demonstrates clinical efficacy in improving the signs and symptoms of mild eczematous skin.
• SPM represents a promising therapeutic agent for managing chronic inflammatory skin conditions with a favorable safety profile.